BibTex format
@article{Celsa:2026:10.1016/j.jhepr.2025.101685,
author = {Celsa, C and Pressiani, T and Nishida, N and Chamseddine, SM and Arvind, A and Li, M and Fortuny, M and Khaled, NB and Iavarone, M and Toyoda, H and Rapposelli, IG and Casadei-Gardini, A and Vivaldi, C and Ulahannan, S and Andanamala, H and Scheiner, B and Pinter, M and Orlandi, E and Fulgenzi, CAM and Manfredi, GF and Lombardi, P and D'Alessio, A and Stefanini, B and Villani, R and Ponziani, FR and Stella, L and Carminati, O and Ricci, AD and Gonzalez, M and Sparacino, A and Di, Maria G and Vaccaro, M and Cabibbo, G and Cammà, C and Reig, M and Kelley, RK and Singal, AG and Kaseb, AO and Kudo, M and Rimassa, L and Pinato, DJ},
doi = {10.1016/j.jhepr.2025.101685},
journal = {JHEP Rep},
title = {Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.},
url = {http://dx.doi.org/10.1016/j.jhepr.2025.101685},
volume = {8},
year = {2026}
}
RIS format (EndNote, RefMan)
TY - JOUR
AB - BACKGROUND & AIMS: Durvalumab plus tremelimumab (STRIDE) has emerged as a first-line systemic treatment option for unresectable hepatocellular carcinoma (HCC). This international multicentre study aimed to evaluate the efficacy and tolerability of STRIDE or durvalumab monotherapy in routine clinical practice, comparing outcomes between patients within and outside key eligibility criteria for the HIMALAYA trial. METHODS: From a database of 1,423 patients with advanced/unresectable HCC treated with immunotherapy across 35 centres, we analysed 233 patients receiving STRIDE or durvalumab monotherapy. Patients were categorized as HIMALAYA-IN or HIMALAYA-OUT based on key trial eligibility criteria (no prior systemic therapy, ECOG-PS 0-1, Child-Pugh class A, no Vp4 thrombosis). Baseline characteristics were assessed for overall survival (OS) and hepatic decompensation using a multivariable Cox model and competing-risk analysis, respectively. Objective response rates and treatment-related adverse events were recorded. RESULTS: Of the 233 patients, 123 (53%) were HIMALAYA-IN and 110 (47%) were HIMALAYA-OUT. STRIDE was given in 95% of HIMALAYA-IN patients. After median follow-up of 6.0 months, median OS was 20.4 months (95% CI 11.7-NR) in the overall population. HIMALAYA-IN patients achieved significantly longer OS than HIMALAYA-OUT patients (23.0 vs. 12.2 months; hazard ratio 0.61; 95% CI 0.39-0.96; p = 0.03). Macrovascular invasion and hepatic decompensation were independent negative prognostic factors in the whole cohort. Hepatic decompensation occurred in 10.5% of patients within 12 months from treatment start. Objective response rate was 23.7% and 17.8% of HIMALAYA-IN and -OUT patients, respectively. Patients achieving disease control (whole cohort: 59.4%) demonstrated 24-month OS of 58.2% in HIMALAYA-IN and 44.8% in HIMALAYA-OUT groups. Grade 3-4 treatment-related adverse events occurred in 16.3% of patients. CONCLUSIONS: STRIDE shows reproducible effectiveness and
AU - Celsa,C
AU - Pressiani,T
AU - Nishida,N
AU - Chamseddine,SM
AU - Arvind,A
AU - Li,M
AU - Fortuny,M
AU - Khaled,NB
AU - Iavarone,M
AU - Toyoda,H
AU - Rapposelli,IG
AU - Casadei-Gardini,A
AU - Vivaldi,C
AU - Ulahannan,S
AU - Andanamala,H
AU - Scheiner,B
AU - Pinter,M
AU - Orlandi,E
AU - Fulgenzi,CAM
AU - Manfredi,GF
AU - Lombardi,P
AU - D'Alessio,A
AU - Stefanini,B
AU - Villani,R
AU - Ponziani,FR
AU - Stella,L
AU - Carminati,O
AU - Ricci,AD
AU - Gonzalez,M
AU - Sparacino,A
AU - Di,Maria G
AU - Vaccaro,M
AU - Cabibbo,G
AU - Cammà,C
AU - Reig,M
AU - Kelley,RK
AU - Singal,AG
AU - Kaseb,AO
AU - Kudo,M
AU - Rimassa,L
AU - Pinato,DJ
DO - 10.1016/j.jhepr.2025.101685
PY - 2026///
TI - Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.
T2 - JHEP Rep
UR - http://dx.doi.org/10.1016/j.jhepr.2025.101685
UR - https://www.ncbi.nlm.nih.gov/pubmed/41675370
VL - 8
ER -